Cargando…
Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries
BACKGROUND: The preoperative selection of patients with lung cancer recurrence remains a major clinical challenge. Several aspects of this kind of surgery are still insufficiently evidence-based, with only a few series with more than 50 patients. METHODS: A retrospective study on 29 patients who und...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971423/ https://www.ncbi.nlm.nih.gov/pubmed/29807542 http://dx.doi.org/10.1186/s12957-018-1398-2 |
_version_ | 1783326286194671616 |
---|---|
author | Subotic, Dragan Molins, Laureano Soldatovic, Ivan Moskovljevic, Dejan Collado, Lucia Hernández, Jorge |
author_facet | Subotic, Dragan Molins, Laureano Soldatovic, Ivan Moskovljevic, Dejan Collado, Lucia Hernández, Jorge |
author_sort | Subotic, Dragan |
collection | PubMed |
description | BACKGROUND: The preoperative selection of patients with lung cancer recurrence remains a major clinical challenge. Several aspects of this kind of surgery are still insufficiently evidence-based, with only a few series with more than 50 patients. METHODS: A retrospective study on 29 patients who underwent a completion pneumonectomy for postoperative lung cancer recurrence or new primary was done in the period between October 2004 and December 2015. Inclusion criteria include complete (R0) first and second resections, histologically proven recurrent or new malignancy, complete pathohistological report after both operations, and exact data about the treatment outcome at the time of the last contact with patients or their families. RESULTS: There were 25 (86.2%) males and 4 (13.8%) females (M:F 6.2:1). In 13/29 patients, the interval between the first and second operations was less than 2 years, while in the remaining 16 patients, it was longer than 2 years. Concerning the operative stage distribution, stage I was more frequent after the first operation (44.8 vs. 22%), while stage III was dominant after the second operation (40.7 vs. 10.3%). The same tumor histology after the first and second operations existed in 24 (82.8%) patients. Adjuvant treatment was given to 53.6% of patients after the first and to 45.5% of patients after the second operation. The overall 5-year survival was 30%, median survival being 35 ± 16.9 months (1.896, 68.104 95% CI). A median survival of patients in post-surgery stage I after re-do surgery was better in comparison with that in higher stages (35 ± 22.6 vs.17.2 ± 15.1 vs. 21 ± 6.7 months, p > 0.05). Patients with the same tumor type at both operations lived significantly longer (median survival 48 ± 21.5 vs. 7.7 ± 1.9 months) than patients with different tumor histology after the second operation. Patients under 60 years (42.9%) lived longer than patients older than 60 years (median survival 69 ± 4.5 vs. 17.2 ± 14.3 months). The Cox regression analysis revealed only the disease stage at first operation and the same/different tumor histology as significant prognostic factors. One patient died from cardiac insufficiency caused by bronchopleural fistula (3.4% operative mortality). Operative morbidity was 34.4%. CONCLUSION: Completion pneumonectomy may be a reasonable option for postoperative lung cancer recurrence or new primaries only in carefully selected patients, in whom the potential oncological benefits overweigh the surgical risk. |
format | Online Article Text |
id | pubmed-5971423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59714232018-05-30 Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries Subotic, Dragan Molins, Laureano Soldatovic, Ivan Moskovljevic, Dejan Collado, Lucia Hernández, Jorge World J Surg Oncol Research BACKGROUND: The preoperative selection of patients with lung cancer recurrence remains a major clinical challenge. Several aspects of this kind of surgery are still insufficiently evidence-based, with only a few series with more than 50 patients. METHODS: A retrospective study on 29 patients who underwent a completion pneumonectomy for postoperative lung cancer recurrence or new primary was done in the period between October 2004 and December 2015. Inclusion criteria include complete (R0) first and second resections, histologically proven recurrent or new malignancy, complete pathohistological report after both operations, and exact data about the treatment outcome at the time of the last contact with patients or their families. RESULTS: There were 25 (86.2%) males and 4 (13.8%) females (M:F 6.2:1). In 13/29 patients, the interval between the first and second operations was less than 2 years, while in the remaining 16 patients, it was longer than 2 years. Concerning the operative stage distribution, stage I was more frequent after the first operation (44.8 vs. 22%), while stage III was dominant after the second operation (40.7 vs. 10.3%). The same tumor histology after the first and second operations existed in 24 (82.8%) patients. Adjuvant treatment was given to 53.6% of patients after the first and to 45.5% of patients after the second operation. The overall 5-year survival was 30%, median survival being 35 ± 16.9 months (1.896, 68.104 95% CI). A median survival of patients in post-surgery stage I after re-do surgery was better in comparison with that in higher stages (35 ± 22.6 vs.17.2 ± 15.1 vs. 21 ± 6.7 months, p > 0.05). Patients with the same tumor type at both operations lived significantly longer (median survival 48 ± 21.5 vs. 7.7 ± 1.9 months) than patients with different tumor histology after the second operation. Patients under 60 years (42.9%) lived longer than patients older than 60 years (median survival 69 ± 4.5 vs. 17.2 ± 14.3 months). The Cox regression analysis revealed only the disease stage at first operation and the same/different tumor histology as significant prognostic factors. One patient died from cardiac insufficiency caused by bronchopleural fistula (3.4% operative mortality). Operative morbidity was 34.4%. CONCLUSION: Completion pneumonectomy may be a reasonable option for postoperative lung cancer recurrence or new primaries only in carefully selected patients, in whom the potential oncological benefits overweigh the surgical risk. BioMed Central 2018-05-28 /pmc/articles/PMC5971423/ /pubmed/29807542 http://dx.doi.org/10.1186/s12957-018-1398-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Subotic, Dragan Molins, Laureano Soldatovic, Ivan Moskovljevic, Dejan Collado, Lucia Hernández, Jorge Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries |
title | Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries |
title_full | Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries |
title_fullStr | Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries |
title_full_unstemmed | Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries |
title_short | Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries |
title_sort | completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971423/ https://www.ncbi.nlm.nih.gov/pubmed/29807542 http://dx.doi.org/10.1186/s12957-018-1398-2 |
work_keys_str_mv | AT suboticdragan completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries AT molinslaureano completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries AT soldatovicivan completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries AT moskovljevicdejan completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries AT colladolucia completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries AT hernandezjorge completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries |